PDF(Pubmed)
Abstract：
Infections due to carbapenem-resistant Enterobacterales (CRE) are increasingly prevalent in children and are associated with poor clinical outcomes, especially in critically ill patients. Novel beta lactam antibiotics, including ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, and cefiderocol, have been released in recent years to face the emerging challenge of multidrug-resistant (MDR) Gram-negative bacteria. Nonetheless, several novel agents lack pediatric indications approved by the Food and Drug Administration (FDA) and the European Medicine Agency (EMA), leading to uncertain pediatric-specific treatment strategies and uncertain dosing regimens in the pediatric population. In this narrative review we have summarized the available clinical and pharmacological data, current limitations and future prospects of novel beta lactam antibiotics in the pediatric population.
摘要：
耐碳青霉烯类肠杆菌（CRE）感染在儿童中越来越普遍，并与不良的临床结局相关。尤其是危重病人。新型β-内酰胺类抗生素,包括头孢特洛赞-他唑巴坦,头孢他啶-阿维巴坦,美罗培南-瓦巴坦,亚胺培南-西司他丁-来巴坦，还有头孢德罗,近年来已经发布，以应对多重耐药（MDR）革兰氏阴性菌的新挑战。尽管如此，几种新型药物缺乏食品和药物管理局（FDA）和欧洲药品管理局（EMA）批准的儿科适应症，导致儿科人群中不确定的儿科特异性治疗策略和不确定的给药方案。在这篇叙述性综述中，我们总结了可用的临床和药理学数据，新型β-内酰胺抗生素在儿科人群中的当前局限性和未来前景。
